Menu Search
Equities

Tempus AI Inc

TEM*:MEX

Tempus AI Inc

Actions
  • Price (MXN)1,157.02
  • Today's Change-22.86 / -1.94%
  • Shares traded14.68k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

  • Revenue in USD (TTM)640.44m
  • Net income in USD-800.71m
  • Incorporated2015
  • Employees2.30k
  • Location
    Tempus AI Inc600 West Chicago Avenue, Suite 510CHICAGO 60654United StatesUSA
  • Fax+1 (302) 655-5049
  • Websitehttps://www.tempus.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TEM:NSQ since
announced		Transaction
value
Ambry Genetics CorpAnnounced04 Nov 202404 Nov 2024Announced27.23%600.00m
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.